Fatigue News and Research

RSS

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD reported that final results from a Phase III study of 'Victrelis', its investigational oral hepatitis C protease inhibitor, added to peginterferon alfa-2a marketed by Roche Products Limited, and ribavirin therapy were presented for the first time today as part of a late-breaker poster session at The International Liver Congress / 46th European Association for the Study of the Liver annual meeting.

2 Apr 2011

Pediatrician suggests tips to combat allergic symptoms

One of the problems that parents may have during the springtime is deciphering whether their children's sneezing is due to a cold or allergies.

1 Apr 2011

New study examines psychological, social challenges of women with breast cancer

When an aggressive form of breast cancer strikes a young woman, what kind of stress, anxiety and other psychological and social challenges does she face?

1 Apr 2011

Study: Internet-based intervention can improve childhood sleep problems

A study in the April 1 issue of the journal SLEEP demonstrates that an Internet-based intervention was effective at reducing infant and toddler sleep disturbances, as well as providing positive, indirect benefits for maternal sleep, mood and confidence.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Boceprevir drug can help cure hard-to-treat hepatitis C

The drug boceprevir helps cure hard-to-treat hepatitis C, says Saint Louis University investigator Bruce R. Bacon, M.D., author of the March 31 New England Journal of Medicine article detailing the study's findings.

31 Mar 2011

Tips on neurobiology of learning

Everyone would like MDs to have the best education - and to absorb what they are taught. The lead article in the April 4 issue of the journal Academic Medicine connects research on how the brain learns to how to incorporate this understanding into real world education, particularly the education of doctors.

31 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

EC grants marketing authorization for GSK, Valeant's Trobalt to treat epilepsy

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced today that the European Commission has granted marketing authorisation for Trobalt as an adjunctive treatment of partial onset seizures, with or without secondary generalisation in adults aged 18 years and above with epilepsy.

30 Mar 2011

Medical expert says PSTD cases may increase following Japanese tsunami

The Japanese tsunami took quite a massive toll, injuring and killing thousands and causing billions of dollars in destruction. But looking beyond physical destruction, the tsunami took an emotional toll on many as well.

29 Mar 2011

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

Interventional radiologists have been the leaders in the use of intra-arterial yttrium-90 radioembolization, since its introduction in 2000, to treat liver cancer.

29 Mar 2011

Altitude Research Center receives Department of Defense grant to prevent AMS in soldiers

As the American military rushes to confront adversaries in some of the world's highest mountain ranges, the Department of Defense is giving $4 million to the Altitude Research Center at the University of Colorado School of Medicine to develop revolutionary ways to combat high altitude sickness in soldiers, sailors and marines.

29 Mar 2011

Prostate cancer updates

A Hunter-based prostate cancer support group says ground-breaking research by the University of Newcastle will help save many lives in the region. This new work has found patients with localized advanced prostate cancer can double their chances of survival by undertaking hormone therapy in combination with radiology treatment. This comes from a 10 year trial, coordinated by the University's Professor Jim Debnam.

28 Mar 2011

From fatigued to fantastic! You CAN effectively treat CFS, fatigue, fibromyalgia and muscle pain

The “perfect storm” for Fibromyalgia, CFS/ME, and fatigue in general is preparing to hit. A combination of poor nutrition, decreasing sleep, increasing stress and environmental toxins has created a human energy crisis of unprecedented proportions. Over the past 10 years, the incidence of Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FMS) has exploded by 400 to 1000 percent, as documented in five separate studies. The numbers for those with CFS in the U.S., previously estimated at 500,000, are now being re-tallied at closer to 1- 2.5 million. Previous estimates placed the number of Americans with FMS at 6 million. Studies worldwide suggest this has likely gone up in the last decade to ~ 12-24 million Americans! Meanwhile, ¼ of Americans suffer with chronic pain and most are fatigued.

28 Mar 2011

Inflammatory bowel disease in children - Delays in diagnosis common

Once a medical rarity in children, inflammatory bowel disease today is increasingly common in kids, but many of them may not be diagnosed in a timely manner, according to experts from the Pediatric Inflammatory Bowel Disease Center at Johns Hopkins Children’s Center.

28 Mar 2011

U.S. FDA approves Yervoy to treat patients with late-stage melanoma

The U.S. Food and Drug Administration today approved Yervoy to treat patients with late-stage melanoma, the most dangerous type of skin cancer.

28 Mar 2011

Lupus nephritis ESRD study finds increase in incidence rates among children, African Americans

New research documenting changes in the incidence and outcomes of end-stage renal disease in the U.S. between 1995 and 2006, found a significant increase in incidence rates among patients 5 to 39 years of age and in African Americans.

28 Mar 2011

New study: Women with early stage breast cancer worry about recurrence

A new study has found that certain types of women with early stage breast cancer are vulnerable to excessive worrying about cancer recurrence. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also indicates that worrying about cancer recurrence can compromise patients' medical care and quality of life.

28 Mar 2011